Logo image of ASND

ASCENDIS PHARMA A/S - ADR (ASND) Stock Fundamental Analysis

NASDAQ:ASND - Nasdaq - US04351P1012 - ADR - Currency: USD

162  +1.95 (+1.22%)

After market: 162.81 +0.81 (+0.5%)

Fundamental Rating

3

ASND gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. ASND may be in some trouble as it scores bad on both profitability and health. ASND is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ASND had negative earnings in the past year.
ASND had a negative operating cash flow in the past year.
ASND had negative earnings in each of the past 5 years.
In the past 5 years ASND always reported negative operating cash flow.
ASND Yearly Net Income VS EBIT VS OCF VS FCFASND Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

ASND has a better Return On Assets (-32.05%) than 63.81% of its industry peers.
Industry RankSector Rank
ROA -32.05%
ROE N/A
ROIC N/A
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ASND Yearly ROA, ROE, ROICASND Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

With an excellent Gross Margin value of 87.83%, ASND belongs to the best of the industry, outperforming 90.02% of the companies in the same industry.
In the last couple of years the Gross Margin of ASND has grown nicely.
ASND does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.83%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
ASND Yearly Profit, Operating, Gross MarginsASND Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

ASND does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ASND has more shares outstanding
The number of shares outstanding for ASND has been increased compared to 5 years ago.
ASND has a better debt/assets ratio than last year.
ASND Yearly Shares OutstandingASND Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ASND Yearly Total Debt VS Total AssetsASND Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of 0.62, we must say that ASND is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 0.62, ASND is doing good in the industry, outperforming 67.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 0.62
ROIC/WACCN/A
WACC6.65%
ASND Yearly LT Debt VS Equity VS FCFASND Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M 800M

2.3 Liquidity

A Current Ratio of 1.17 indicates that ASND should not have too much problems paying its short term obligations.
The Current ratio of ASND (1.17) is worse than 86.45% of its industry peers.
ASND has a Quick Ratio of 1.17. This is a bad value and indicates that ASND is not financially healthy enough and could expect problems in meeting its short term obligations.
ASND has a worse Quick ratio (0.84) than 90.73% of its industry peers.
Industry RankSector Rank
Current Ratio 1.17
Quick Ratio 0.84
ASND Yearly Current Assets VS Current LiabilitesASND Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.12% over the past year.
ASND shows a strong growth in Revenue. In the last year, the Revenue has grown by 36.34%.
ASND shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 93.57% yearly.
EPS 1Y (TTM)34.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.3%
Revenue 1Y (TTM)36.34%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%5.28%

3.2 Future

Based on estimates for the next years, ASND will show a very strong growth in Earnings Per Share. The EPS will grow by 35.79% on average per year.
ASND is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 49.48% yearly.
EPS Next Y39.83%
EPS Next 2Y48.04%
EPS Next 3Y45.83%
EPS Next 5Y35.79%
Revenue Next Year101.64%
Revenue Next 2Y87.41%
Revenue Next 3Y76.38%
Revenue Next 5Y49.48%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ASND Yearly Revenue VS EstimatesASND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B
ASND Yearly EPS VS EstimatesASND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ASND reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 113.80, ASND can be considered very expensive at the moment.
88.24% of the companies in the same industry are more expensive than ASND, based on the Price/Forward Earnings ratio.
ASND is valuated expensively when we compare the Price/Forward Earnings ratio to 21.76, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 113.8
ASND Price Earnings VS Forward Price EarningsASND Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ASND Per share dataASND EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 -6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
ASND's earnings are expected to grow with 45.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.04%
EPS Next 3Y45.83%

More info and screens

0

5. Dividend

5.1 Amount

ASND does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASCENDIS PHARMA A/S - ADR

NASDAQ:ASND (5/23/2025, 9:14:07 PM)

After market: 162.81 +0.81 (+0.5%)

162

+1.95 (+1.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-01 2025-05-01/amc
Earnings (Next)09-01 2025-09-01/amc
Inst Owners110.13%
Inst Owner Change2.79%
Ins Owners0.78%
Ins Owner ChangeN/A
Market Cap9.74B
Analysts86.96
Price Target226.12 (39.58%)
Short Float %6.55%
Short Ratio7.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.8%
Min EPS beat(2)3.09%
Max EPS beat(2)34.5%
EPS beat(4)2
Avg EPS beat(4)-11.98%
Min EPS beat(4)-50.09%
Max EPS beat(4)34.5%
EPS beat(8)5
Avg EPS beat(8)0.52%
EPS beat(12)6
Avg EPS beat(12)-2.69%
EPS beat(16)9
Avg EPS beat(16)3.08%
Revenue beat(2)1
Avg Revenue beat(2)5.64%
Min Revenue beat(2)-31.16%
Max Revenue beat(2)42.44%
Revenue beat(4)2
Avg Revenue beat(4)-7.11%
Min Revenue beat(4)-57.97%
Max Revenue beat(4)42.44%
Revenue beat(8)5
Avg Revenue beat(8)20.09%
Revenue beat(12)9
Avg Revenue beat(12)24.15%
Revenue beat(16)11
Avg Revenue beat(16)20.23%
PT rev (1m)6.75%
PT rev (3m)12.93%
EPS NQ rev (1m)-0.14%
EPS NQ rev (3m)-9.25%
EPS NY rev (1m)-8.01%
EPS NY rev (3m)-0.16%
Revenue NQ rev (1m)1.33%
Revenue NQ rev (3m)-0.6%
Revenue NY rev (1m)9.04%
Revenue NY rev (3m)19.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 113.8
P/S 23.68
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-6.62
EYN/A
EPS(NY)1.42
Fwd EY0.88%
FCF(TTM)-5.79
FCFYN/A
OCF(TTM)-5.76
OCFYN/A
SpS6.84
BVpS-1.99
TBVpS-2.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.05%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.83%
FCFM N/A
ROA(3y)-47.96%
ROA(5y)-44.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.06%
GM growth 5YN/A
F-Score4
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.06%
Cap/Sales 0.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.17
Quick Ratio 0.84
Altman-Z 0.62
F-Score4
WACC6.65%
ROIC/WACCN/A
Cap/Depr(3y)33.9%
Cap/Depr(5y)97.41%
Cap/Sales(3y)9.88%
Cap/Sales(5y)130.23%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%31.3%
EPS Next Y39.83%
EPS Next 2Y48.04%
EPS Next 3Y45.83%
EPS Next 5Y35.79%
Revenue 1Y (TTM)36.34%
Revenue growth 3Y260.22%
Revenue growth 5Y93.57%
Sales Q2Q%5.28%
Revenue Next Year101.64%
Revenue Next 2Y87.41%
Revenue Next 3Y76.38%
Revenue Next 5Y49.48%
EBIT growth 1Y38.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.64%
EBIT Next 3Y53.81%
EBIT Next 5YN/A
FCF growth 1Y34.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.48%
OCF growth 3YN/A
OCF growth 5YN/A